CA2285852C - Comprime pharmaceutique comprenant du lisinoprile disodique et de la cellulose microcristalline - Google Patents

Comprime pharmaceutique comprenant du lisinoprile disodique et de la cellulose microcristalline Download PDF

Info

Publication number: CA2285852C
Authority: CA; Canada
Prior art keywords: lisinopril; disodium; microcrystalline cellulose; water; mass
Prior art date: 1999-10-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 2285852

Other languages

English (en)

Other versions

CA2285852A1 (fr

Inventor

Bernard Charles Sherman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-26

Filing date

1999-10-26

Publication date

2001-04-03

1999-10-26 Application filed by Individual filed Critical Individual

1999-10-26 Priority to CA 2285852 priority Critical patent/CA2285852C/fr

2000-01-04 Publication of CA2285852A1 publication Critical patent/CA2285852A1/fr

2001-04-03 Application granted granted Critical

2001-04-03 Publication of CA2285852C publication Critical patent/CA2285852C/fr

2019-10-26 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 title claims abstract description 49
108010007859 Lisinopril Proteins 0.000 title claims abstract description 48
229960002394 lisinopril Drugs 0.000 title claims abstract description 46
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 title claims abstract description 28
229920000168 Microcrystalline cellulose Polymers 0.000 title claims abstract description 13
235000019813 microcrystalline cellulose Nutrition 0.000 title claims abstract description 13
239000008108 microcrystalline cellulose Substances 0.000 title claims abstract description 13
229940016286 microcrystalline cellulose Drugs 0.000 title claims abstract description 13
238000000034 method Methods 0.000 claims abstract description 6
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
239000007787 solid Substances 0.000 claims abstract 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 8
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
238000001035 drying Methods 0.000 claims description 3
239000000314 lubricant Substances 0.000 claims description 3
239000000243 solution Substances 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
239000008101 lactose Substances 0.000 description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 3
239000012439 solid excipient Substances 0.000 description 3
239000005541 ACE inhibitor Substances 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
239000012530 fluid Substances 0.000 description 2
-1 for example Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
159000000011 group IA salts Chemical class 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229960005368 lisinopril anhydrous Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011812 mixed powder Substances 0.000 description 1
229940088953 prinivil Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
150000003388 sodium compounds Chemical class 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
229940072252 zestril Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)

CA 2285852 1999-10-26 1999-10-26 Comprime pharmaceutique comprenant du lisinoprile disodique et de la cellulose microcristalline Expired - Fee Related CA2285852C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2285852 CA2285852C (fr)	1999-10-26	1999-10-26	Comprime pharmaceutique comprenant du lisinoprile disodique et de la cellulose microcristalline

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2285852 CA2285852C (fr)	1999-10-26	1999-10-26	Comprime pharmaceutique comprenant du lisinoprile disodique et de la cellulose microcristalline

Publications (2)

Publication Number	Publication Date
CA2285852A1 CA2285852A1 (fr)	2000-01-04
CA2285852C true CA2285852C (fr)	2001-04-03

Family

ID=4164363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2285852 Expired - Fee Related CA2285852C (fr)	1999-10-26	1999-10-26	Comprime pharmaceutique comprenant du lisinoprile disodique et de la cellulose microcristalline

Country Status (1)

Country	Link
CA (1)	CA2285852C (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6462174B1 (en)	2001-06-25	2002-10-08	Astrazeneca Ab	Amorphous compound
US6458769B1 (en)	2001-06-25	2002-10-01	Astrazeneca Ab	Amorphous compound
US6627760B1 (en)	2001-06-25	2003-09-30	Astrazeneca Ab	Amorphous compound

1999
- 1999-10-26 CA CA 2285852 patent/CA2285852C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2285852A1 (fr)	2000-01-04

Similar Documents

Publication	Publication Date	Title
KR100696350B1 (ko)	2007-03-20	급속 방출 정제
US10307400B2 (en)	2019-06-04	Orally disintegrating tablet containing asenapine
KR20010024184A (ko)	2001-03-26	활성 성분으로 클로드로네이트, 부형제로 실리시파이드미세결정성 셀룰로즈를 함유하는 의약 제제
CN1145479C (zh)	2004-04-14	药物制剂
CA2662265A1 (fr)	2008-03-06	Compositions d'imatinib
US8193226B2 (en)	2012-06-05	Candesartan cilexetil
KR20010071765A (ko)	2001-07-31	제약학적 레보타이록신 제제
ZA200409237B (en)	2005-07-14	Immediate release pharmaceutical formulation.
KR101230178B1 (ko)	2013-02-06	골다공증 예방 또는 치료용 조성물 및 이의 제조방법
KR20050039732A (ko)	2005-04-29	이부프로펜 결정의 형성 방법
CA2285852C (fr)	2001-04-03	Comprime pharmaceutique comprenant du lisinoprile disodique et de la cellulose microcristalline
JP2013544272A5 (fr)	2016-06-16
PL384680A1 (pl)	2008-09-29	Kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz sposób jej wytwarzania
WO2008110337A2 (fr)	2008-09-18	Composition pharmaceutique de fumarate de quétiapine
WO2000071117A1 (fr)	2000-11-30	Compositions medicinales a liberation immediate pour administration orale
US7074429B2 (en)	2006-07-11	Fosinopril sodium tablet formulation
WO2004045584A1 (fr)	2004-06-03	Formes pharmaceutiques solides a l'hydrochlorure de bupropione
EP2303233A1 (fr)	2011-04-06	Forme galénique orale solide contenant l agent anti-plaquettaire clopidogrel et son procédé de préparation
KR100653388B1 (ko)	2006-12-05	안정성이 우수한 ａｃｅ 저해제를 포함하는 약제학적 조성물
KR100679166B1 (ko)	2007-02-06	안정성이 증진된 약제학적 조성물 및 그의 제조방법
WO2008133537A1 (fr)	2008-11-06	Composition pharmaceutique à stabilité améliorée comprenant un inhibiteur de l'ace ou un de ses sels pharmacocompatibles, et leurs méthodes de fabrication
TR2023003669A1 (tr)	2024-10-21	Empagliflozi̇n i̇çeren kati bi̇r di̇spersi̇yonun bi̇r tablet formülasyonu
JP4040221B2 (ja)	2008-01-30	エナラプリル塩を安定化した製剤及びその方法
CA2303481A1 (fr)	2001-10-05	Compositions pharmaceutiques comprenant du moexipril et du magnesium
KR100561025B1 (ko)	2006-03-17	직접 타정법에 의해 제조되며 보관안정성이 증진된 라미프릴 정제

Legal Events

Date	Code	Title	Description
1999-10-26	EEER	Examination request
2002-10-28	MKLA	Lapsed